A 'performance curve' chart for containers could simplify the design process
Logistics managers in life sciences and personal care focus on transportation capacity
Real business value arises from going beyond simple regulatory compliance for California's e-pedigree mandate
First-ever study of the impact of REMS on supply chains finds that collaboration is a critical requirement
The emergence of natural language processing in pharmacovigilance
Looking at 'cost' and 'value' under different evaluation processes
Advanced label technologies serve functions far beyond product identification
New incentives for health plans could alter the way payers review new drugs
Getting away from the traditional product-centric management structure is not easy; here’s how to do it
Drivers in the post-healthcare-reform world
While pharma manufacturers may be concerned about the impact of item-level inventory tracking, it's an idea that actually makes great business sense
Addressing patient recruitment and retention issues is a natural role for CTEs
PwC's annual forecast of the year's most important healthcare trends
Outsourced services can provide significant financial and risk-avoidance benefits
Sharing clinical data—EvGen—will improve both drug development and health outcomes analysis
Collecting and reporting data in near real time cuts costs and reduces risk
A direct-distribution model could save expense for payers and patients while providing better service
Commercial teams can prepare for overcoming predictable hurdles
Stable economics and growing healthcare concerns make Brazil one of the top emerging markets, with a current growth rate >20%
Following are excerpts from the keynote presentation of Steven C. Anderson, president and CEO of the National Assn. of Chain Drug Stores, at its annual meeting, Palm Beach, FL, Apr. 25.
Electronic health-record systems (EHRs) are bringing needed drug information to the point of care for prescribers
Carving out CGTs for payment systems involving government intervention may be an answer
While the pharma industry is growing more dependent on companion diagnostics, test developers face an uncertain business model
Paper validation records will disappear in the face of continuous validation
Both promise and peril exist for drugmakers in working with diagnostic tests to commercialize new medications or refine the applicability of existing ones
Team-Up seeks to bring manufacturers and logistics providers together
Today’s evolving healthcare environment calls for more collaboration in bringing drugs to market